Home

PAUL V MAIER

CIK 1182615 · Chief Financial Officer · last filed 2026-06-23

PAUL V MAIER is a Chief Financial Officer who has filed 130 SEC Form 4 insider transactions across 8 companies since 2008. Across all open-market trades the lifetime net is +$33.6K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $2.8M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.79M

Companies

8

Total Filings

130

Lifetime Open-Market Net

$33.6K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ETON Director 59,745 $46.65 $2.79M $30.0K 9 2026-01-14
Ambrx Biopharma, Inc. (AMAM) Delisted Director 85,000 $28.00 $2.38M $0 3 2024-03-07
Qualigen Therapeutics, Inc. (RTTR) Delisted Director — — — $0 5 2020-01-17
MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX) Delisted Director 23,063 — — -$30.3K 12 2018-04-04
SEELOS THERAPEUTICS, INC. (APRI) Delisted Director 462 — — $0 11 2018-01-08
SEQUENOM INC (SQNM) Delisted Chief Financial Officer 76,927 — — $28.6K 18 2014-02-12
PURE BIOSCIENCE, INC. (PURE) Delisted Director 8,639 — — $0 2 2012-08-02
Talon Therapeutics, Inc. (HNAB) Delisted Director 1,750 — — $5.2K 4 2009-02-26

Recent Filings

130 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-23 — Grant (A) — $0
2026-01-14 ETON Grant (A) — $0 EDGAR
2025-06-20 — Grant (A) — $0
2025-01-06 ETON Grant (A) — $0 EDGAR
2024-06-13 — Grant (A) — $0
2024-03-07 Ambrx Biopharma, Inc. (AMAM) Delisted Disp (D) — $0 EDGAR
2024-02-15 ETON Grant (A) — $0 EDGAR
2023-06-16 — Grant (A) — $0
2023-06-09 Ambrx Biopharma, Inc. (AMAM) Delisted Grant (A) +85,000 $0 EDGAR
2023-03-03 ETON Grant (A) — $0 EDGAR
Showing 1–10 of 130
Page 1 of 13
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.